Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on Crizotinib and at least 1 other ALK inhibitor, OR Alectinib or ceritinib as first ALK inhibitor therapy Condition: Normal Hepatic Function |
Dose: PO – 100 mg Frequency: once daily Note: With or without food. Continue until disease progression or unacceptable toxicity. |
|
Indication: Anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on Crizotinib and at least 1 other ALK inhibitor, OR Alectinib or ceritinib as first ALK inhibitor therapy Condition: Mild hepatic impairment (total bilirubin less than or equal to Upper Limit of Normal with AST greater than Upper Limit of Normal or total bilirubin greater than 1-1.5x Upper Limit of Normal with any AST) |
Dose: PO – 100 mg Frequency: once daily Note: No dose adjustment necessary. With or without food. Continue until disease progression or unacceptable toxicity. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: No approved pediatric dosage available Note: No approved pediatric dosage available |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Mild or moderate renal impairment (Creatinine Clearance 30-89 mL/minute) |
Dose: Not specified Note: No dosage adjustment necessary |
|
Condition: Severe renal impairment (Creatinine Clearance less than 30 mL/minute) |
Dose: Not specified Note: Recommended dose not established |
Administration
- Take once daily
- With or without food
Side Effect
- Hypercholesterolemia (96%)
- Hypertriglyceridemia (90%)
- Edema (57%)
- Hyperglycemia (52%)
- Anemia (52%)
- Peripheral neuropathy (47%)
- Increased AST (37%)
- Hypoalbuminemia (33%)
- Increased ALT (28%)
- Cognitive effects (27%)
- Dyspnea (27%)
- Fatigue (26%)
- Weight gain (24%)
- Increased lipase (24%)
- Increased alkaline phosphatase (24%)
- Thrombocytopenia (23%)
- Arthralgia (23%)
- Mood effects (23%)
- Diarrhea (22%)
- Increased amylase (22%)
- Lymphopenia (22%)
- Hyperkalemia (21%)
- Hypomagnesemia (21%)
- Headache (18%)
- Cough (18%)
- Nausea (18%)
- Myalgia (17%)
- Dizziness (16%)
- Vision disorder (15%)
- Constipation (15%)
- Rash (14%)
- Back pain (13%)
- Pain in extremity (13%)
- Vomiting (12%)
- Speech effects (12%)
- Pyrexia (12%)
- Upper respiratory tract infection (URTI) (12%)
- Hypercholesterolemia (18%)
- Hypertriglyceridemia (18%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Strong CYP3A inducers
|
May significantly decrease lorlatinib plasma concentrations
|
|
Strong CYP3A inhibitors
|
Increased lorlatinib plasma concentrations
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.